DB
MTACU

Dmitry Balyasny’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Dmitry Balyasny’s Portfolio MTACU Stock Details MTACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500,000
Closed -$5.25M – 2166
2020
Q4 		$5.25M Buy
+500,000
New +$5.22M 0.03% 634

Other funds holding MTACU

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
HP
Hartree Partners New York $469M AUM 46.64% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.24B AUM 137.67% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.57% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Dmitry Balyasny's MTACU Position: Q1 2021 in Review

Dmitry Balyasny sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2021, closing a stake of 500,000 shares — an estimated $5.25M sold.

Dmitry Balyasny first reported a position in MTACU in Q4 2020 and held it in 1 quarter. The position peaked at $5.25M in Q4 2020. 31 funds tracked by Wall St. Rank hold MTACU as of Q1 2021.

  • Dmitry Balyasny reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2021 after selling out during the quarter.
  • Dmitry Balyasny sold 500,000 MedTech Acquisition Corporation Unit shares in Q1 2021, an estimated $5.25M.
  • Dmitry Balyasny first reported a position in MedTech Acquisition Corporation Unit in Q4 2020 and held it in 1 quarter.
  • Dmitry Balyasny's MedTech Acquisition Corporation Unit position peaked at $5.25M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.